BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Prostate cancer AND FOXO1, Q12778, FOXO1A, 2308, ENSG00000150907, FKH1, FKHR AND Treatment
35 results:

  • 1. SGK2 promotes prostate cancer metastasis by inhibiting ferroptosis via upregulating GPX4.
    Cheng L; He Q; Liu B; Chen L; Lv F; Li X; Li Y; Liu C; Song Y; Xing Y
    Cell Death Dis; 2023 Jan; 14(1):74. PubMed ID: 36720852
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. miR-29b Regulates Lung cancer Progression by Downregulating FEM1B and Inhibiting the FOX01/AKT Pathway.
    Zhang H; Wang R; Deng Q
    Comput Math Methods Med; 2022; 2022():3110330. PubMed ID: 36003920
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Targeting the PLK1-foxo1 pathway as a novel therapeutic approach for treating advanced prostate cancer.
    Gheghiani L; Shang S; Fu Z
    Sci Rep; 2020 Jul; 10(1):12327. PubMed ID: 32704044
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. Cross-Linked Polyphenol-Based Drug Nano-Self-Assemblies Engineered to Blockade prostate cancer Senescence.
    Nagesh PKB; Chowdhury P; Hatami E; Kumari S; Kashyap VK; Tripathi MK; Wagh S; Meibohm B; Chauhan SC; Jaggi M; Yallapu MM
    ACS Appl Mater Interfaces; 2019 Oct; 11(42):38537-38554. PubMed ID: 31553876
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Overcoming EZH2 Inhibitor Resistance by Taxane in PTEN-Mutated cancer.
    Ma L; Yan Y; Bai Y; Yang Y; Pan Y; Gang X; Karnes RJ; Zhang J; Lv Q; Wu Q; Huang H
    Theranostics; 2019; 9(17):5020-5034. PubMed ID: 31410199
    [No Abstract]    [Full Text] [Related]  

  • 6. Nodal pathway activation due to Akt1 suppression is a molecular switch for prostate cancer cell epithelial-to-mesenchymal transition and metastasis.
    Alwhaibi A; Verma A; Artham S; Adil MS; Somanath PR
    Biochem Pharmacol; 2019 Oct; 168():1-13. PubMed ID: 31202735
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Early detection of the PAX3-foxo1 fusion gene in circulating tumor-derived DNA in a case of alveolar rhabdomyosarcoma.
    Eguchi-Ishimae M; Tezuka M; Kokeguchi T; Nagai K; Moritani K; Yonezawa S; Tauchi H; Tokuda K; Ishida Y; Ishii E; Eguchi M
    Genes Chromosomes Cancer; 2019 Aug; 58(8):521-529. PubMed ID: 30739374
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. Norcantharidin enhances antitumor immunity of GM-CSF prostate cancer cells vaccine by inducing apoptosis of regulatory T cells.
    Mo L; Zhang X; Shi X; Wei L; Zheng D; Li H; Gao J; Li J; Hu Z
    Cancer Sci; 2018 Jul; 109(7):2109-2118. PubMed ID: 29770533
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. [Chinese medicinal compound CFF-1 induces the apoptosis and cycle-arrest of prostate cancer cells via the PI3K/AKT/foxo1 signaling pathway].
    Zhang Y; Wu ZM; Lei BH; Lu ZJ; Zhu QY; Xu FS; Zhang MS; Liu P
    Zhonghua Nan Ke Xue; 2017 Sep; 23(9):828-837. PubMed ID: 29726666
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Traditional Chinese Medicine CFF-1 induced cell growth inhibition, autophagy, and apoptosis via inhibiting EGFR-related pathways in prostate cancer.
    Wu Z; Zhu Q; Yin Y; Kang D; Cao R; Tian Q; Zhang Y; Lu S; Liu P
    Cancer Med; 2018 Apr; 7(4):1546-1559. PubMed ID: 29533017
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. miR-141 inhibits prostatic cancer cell proliferation and migration, and induces cell apoptosis via targeting of RUNX1.
    Xu S; Ge J; Zhang Z; Zhou W
    Oncol Rep; 2018 Mar; 39(3):1454-1460. PubMed ID: 29328406
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. Regulatory effects of antitumor agent matrine on FOXO and PI3K-AKT pathway in castration-resistant prostate cancer cells.
    Li Q; Huang H; He Z; Sun Y; Tang Y; Shang X; Wang C
    Sci China Life Sci; 2018 May; 61(5):550-558. PubMed ID: 29119376
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. Loss of foxo1 Cooperates with TMPRSS2-ERG Overexpression to Promote prostate Tumorigenesis and Cell Invasion.
    Yang Y; Blee AM; Wang D; An J; Pan Y; Yan Y; Ma T; He Y; Dugdale J; Hou X; Zhang J; Weroha SJ; Zhu WG; Wang YA; DePinho RA; Xu W; Huang H
    Cancer Res; 2017 Dec; 77(23):6524-6537. PubMed ID: 28986382
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Isorhapontigenin induced cell growth inhibition and apoptosis by targeting EGFR-related pathways in prostate cancer.
    Zhu C; Zhu Q; Wu Z; Yin Y; Kang D; Lu S; Liu P
    J Cell Physiol; 2018 Feb; 233(2):1104-1119. PubMed ID: 28422286
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. AKT-phosphorylated foxo1 suppresses ERK activation and chemoresistance by disrupting IQGAP1-MAPK interaction.
    Pan CW; Jin X; Zhao Y; Pan Y; Yang J; Karnes RJ; Zhang J; Wang L; Huang H
    EMBO J; 2017 Apr; 36(8):995-1010. PubMed ID: 28279977
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. miR-96 promotes the growth of prostate carcinoma cells by suppressing MTSS1.
    Xu L; Zhong J; Guo B; Zhu Q; Liang H; Wen N; Yun W; Zhang L
    Tumour Biol; 2016 Sep; 37(9):12023-12032. PubMed ID: 27164937
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Role of taxanes in advanced prostate cancer.
    Cassinello J; Carballido Rodríguez J; Antón Aparicio L
    Clin Transl Oncol; 2016 Oct; 18(10):972-80. PubMed ID: 26856599
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Estrogen Exhibits a Biphasic Effect on prostate Tumor Growth through the Estrogen Receptor β-KLF5 Pathway.
    Nakajima Y; Osakabe A; Waku T; Suzuki T; Akaogi K; Fujimura T; Homma Y; Inoue S; Yanagisawa J
    Mol Cell Biol; 2016 Jan; 36(1):144-56. PubMed ID: 26483416
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Dual PI3K/mTOR inhibitor, XL765 (SAR245409), shows superior effects to sole PI3K [XL147 (SAR245408)] or mTOR [rapamycin] inhibition in prostate cancer cell models.
    Gravina GL; Mancini A; Scarsella L; Colapietro A; Jitariuc A; Vitale F; Marampon F; Ricevuto E; Festuccia C
    Tumour Biol; 2016 Jan; 37(1):341-51. PubMed ID: 26219891
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Exploitation of the Androgen Receptor to Overcome Taxane Resistance in Advanced prostate cancer.
    Martin SK; Kyprianou N
    Adv Cancer Res; 2015; 127():123-58. PubMed ID: 26093899
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 2.